Eton Pharmaceuticals, Inc.

NASDAQ:ETON

Biotechnology

Healthcare
$61.99 -1.39%

-$0.46 today

Market cap
$1.79B
Beta
0.89
P/E (TTM)
-597.6
EPS (TTM)
-$0.05
52W Low $13.09High $35.66

Volume 0.48M

Average 0.43M

ETON EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Eton Pharmaceuticals, Inc.NASDAQ: ETON

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA grows, but more slowly than its trailing trend

Q1 FY2026 EBITDA of $1.87M rose 175.1% year over year, behind the +504.9% change in trailing-twelve-month EBITDA. Sequentially, it fell 48.7% from the prior quarter.

Context

  • EBITDA amounted to 5.3% of revenue in FY2025, up 3.7 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 3 analysts of $81.62M (+1812.9%) for the fiscal year ending Dec 2026, a step up from the +749.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.87M-48.7% QoQ
Last fiscal yearDec 2025
$4.27M+749.5% YoY
LTMMar 2026
$5.45M+504.9% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+175.1%+3408.2%+3233.1 pp
1 year+749.5%+1812.9%+1063.4 pp
3-year CAGR—+229.3%—
5-year CAGR+127.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
4.27M USD
Year-over-year change
+749.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How ETON compares with its peers on the latest reported figures

  • ETON's LTM Mar 2026 EBITDA of $5.45M is the 3rd highest of the 10 companies compared; the peer median is -$35.03M.
  • Its year-over-year change of +504.9% is the highest of 10, against a peer median of -11.9%.
  • EBITDA amounts to 6.3% of revenue for ETON, versus a peer median of 25.0%.
ETON Competitors Peer median
EBITDA for ETON and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZVRAZevra Therapeutics, Inc.LTM Mar 2026$140.47M +332.9%—114.9%
PHARPharming Group N.V.LTM Mar 2026$39.48M +82.4%-1.9%10.7%
ETONEton Pharmaceuticals, Inc.LTM Mar 2026$5.45M +504.9%—6.3%
FENCFennec Pharmaceuticals Inc.LTM Mar 2026-$6.67M +35.5%—13.1%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026-$17.44M +88.7%—25.0%
DMACDiaMedica Therapeutics Inc.LTM Mar 2026-$35.03M -30.1%——
TVTXTravere Therapeutics, Inc.LTM Sep 2026-$106.58M -372.0%—16.4%
LRMRLarimar Therapeutics, Inc.LTM Mar 2026-$165.68M -74.6%——
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-$473.54M -208.3%—49.3%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026-$503.35M -11.9%—75.2%
Peer median (excluding ETON) -$35.03M-11.9%-1.9%25.0%

Competitors are the stored peer set for ETON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue21.83M21.25M31.64M39.01M79.95M
Cost of Revenue2.62M6.93M10.58M15.6M37.21M
Gross Profit19.21M14.32M21.06M23.41M42.74M
Gross Margin88.0%67.4%66.6%60.0%53.5%
Research & Development6.24M4M3.32M3.26M7.77M
Selling, General & Admin14.47M18.58M18.93M22.75M35.82M
Operating Expenses20.7M22.58M22.25M26.01M42.67M
Depreciation & Amortization462K1.77M901K1.15M4.04M
EBITDA(1.49M)(7.25M)212K(657K)4.27M
EBITDA Margin-6.8%-34.1%0.7%-1.7%5.3%
Operating Income(1.5M)(8.26M)(1.19M)(2.6M)72K
Operating Margin-6.8%-38.9%-3.8%-6.7%0.1%
Interest Income00000
Interest Expense1.04M955K1.06M2.01M4.78M
Other Income / Expenses(460K)(761K)503K(1.21M)(4.63M)
Income Before Tax(1.96M)(9.02M)(689K)(3.81M)(4.56M)
Pre-Tax Margin-9.0%-42.4%-2.2%-9.8%-5.7%
Income Tax Expense00247K15K43K
Net Income(1.96M)(9.02M)(936K)(3.82M)(4.6M)
Net Margin-9.0%-42.4%-3.0%-9.8%-5.8%
EPS (Basic)(0.08)(0.36)(0.04)(0.15)(0.17)
EPS (Diluted)(0.08)(0.36)(0.04)(0.15)(0.17)
Weighted Avg Shares25.21M25.15M25.65M25.9M26.91M
Weighted Avg Shares (Diluted)25.21M25.15M25.65M25.9M26.91M

Eton Pharmaceuticals, Inc.

NASDAQ:ETON

Intrinsic Alpha fair value

Locked

Current Price

$61.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.